Levo Therapeutics has a total of 40 patents globally, out of which 14 have been granted. Of these 40 patents, more than 82% patents are active. United States of America is where Levo Therapeutics has filed the maximum number of patents, followed by Germany and United Kingdom. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Levo Therapeutics.
Levo Therapeutics was founded in the year 2016. The Company is a biomedical research and development services intended to treat the multisystem neurodevelopmental disorder.
Do read about some of the most popular patents of Levo Therapeutics which have been covered by us in this article and also you can find Levo Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Levo Therapeutics patent portfolio.
How many patents does the founder and the CEO of Levo Therapeutics have?
The founder and CEO Sara Cotter has 3 patents.
How many patents does Levo Therapeutics have?
Levo Therapeutics has a total of 40 patents globally. These patents belong to 5 unique patent families. Out of 40 patents, 33 patents are active.
How Many Patents did Levo Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Levo Therapeutics Applications Filed | Levo Therapeutics Patents Granted |
| 2023 | – | 3 |
| 2022 | 4 | 2 |
| 2021 | 4 | 3 |
| 2020 | 1 | 5 |
| 2019 | 10 | 1 |
| 2018 | 3 | – |
| 2017 | 18 | – |
How many Levo Therapeutics patents are Alive/Dead?
How Many Patents did Levo Therapeutics File in Different Countries?
Countries in which Levo Therapeutics Filed Patents
| Country | Patents |
| Israel | 5 |
| Hong Kong (S.A.R.) | 4 |
| Australia | 4 |
| Korea (South) | 3 |
| Mexico | 2 |
| Japan | 2 |
| Europe | 2 |
| New Zealand | 2 |
| Russia | 2 |
| United States Of America | 2 |
| Canada | 1 |
| Germany | 1 |
| Spain | 1 |
| Brazil | 1 |
| South Africa | 1 |
| China | 1 |
| Italy | 1 |
| Austria | 1 |
Where are Research Centres of Levo Therapeutics Patents Located?
List of Levo Therapeutics Patents
| Levo Therapeutics Patents | Title |
| US10842775B2 | Methods Of Treating Prader-Willi Syndrome |
| US20210113521A1 | Methods Of Treating Prader-Willi Syndrome |
| EP3478281B1 | Pde4 Inhibitors For Treating Prader-Willi Syndrome |
| EP3831376A1 | Pde4 Inhibitors For Treating Obesity, Schaaf-Yang Syndrome Or Autism Spectrum Disorder |
| CN109562092B | Treatments For Prader-Willi Syndrome |
| AU2017275652B2 | Methods Of Treating Prader-Willi Syndrome |
| AU2019345166B2 | Stable Intranasal Formulations Of Carbetocin |
| AU2021245104A1 | Stable Intranasal Formulations Of Carbetocin |
| CA3026083A1 | Methods Of Treating Prader-Willi Syndrome |
| HK40058348A | Stable Intranasal Formulations Of Carbetocin |
| HK40058351A | Carbetocin Drug Product And Process For Preparing Same |
| HK40043015A | Pde4 Inhibitors For Treating Obesity, Schaaf-Yang Syndrome Or Autism Spectrum Disorder |
| HK40007454A1 | Pde4 Inhibitors For Treating Prader-Willi Syndrome |
| JP7329634B2 | How To Treat Prader-Willi Syndrome |
| JP7044768B2 | How To Treat Prader-Willi Syndrome |
| IL294407A | Posohodiesterase 4 Inhibitor For Use In A Method Of Terating Diseases Associated With Reduced Pc1 Levels And/Or Activity |
| IL288813A | Stable Intranasal Formulations Of Carbetocin |
| IL281520A | Carbetocin Drug Product And Process For Preparing Same |
| IL281519A | Stable Intranasal Formulations Of Carbetocin |
| IL263412A | Methods Of Treating Prader-Willi Syndrome |
| KR102478186B1 | How To Treat Prader-Willi Syndrome |
| ES2847126T3 | Pde4 Inhibitors For The Treatment Of Prader-Willi Syndrome |
| RU2748294C2 | Method For Treatment Of Prader-Willi Syndrome |
| DE602017028957T2 | Pde4 Inhibitors For The Treatment Of Prader-Willi Syndrome |
| IT202100001568T2 | Pde4 Inhibitors For The Treatment Of Prader-Willi Syndrome |
| MX375277B | Methods To Treat Prader-Willi Syndrome |
| ZA201808607B | Methods Of Treating Prader-Willi Syndrome |
| NZ773548A | Stable Intranasal Formulations Of Carbetocin |
| NZ778868A | Stable Intranasal Formulations Of Carbetocin |
| RU2021114228A | Treatment Of Prader-Willi Syndrome |
| KR1020210062648A | Carbetocin Drug Product And Method For Manufacturing Same |
| MX2020009939A | Methods Of Treating Prader-Willi Syndrome. |
| BR112018075039A2 | Prader-Willi Syndrome Treatment Methods |
| WO2022236296A1 | Therapy For Treatment Of Prader-Willi Syndrome |
| WO2020061414A1 | Stable Intranasal Formulations Of Carbetocin |
| WO2020061416A1 | Carbetocin Drug Product And Process For Preparing Same |
| WO2017210540A1 | Methods Of Treating Prader-Willi Syndrome |
| AU2019345313A1 | Carbetocin Drug Product And Process For Preparing Same |
| KR1020210062638A | Stable Intranasal Formulations Of Carbetocine |
| AT1340122T | Pde4 Inhibitoren Zur Behandlung Des Prader-Willi-Syndroms |
What are Levo Therapeutics’ key innovation segments?
What Technologies are Covered by Levo Therapeutics?
The chart below distributes patents filed by Levo Therapeutics